Physician profile
Joel Appel
NPI 1811935273
$3,349.81
in general payments reported to CMS, 2019-2025
22 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,792 · 2020: $215 · 2022: $618 · 2023: $282 · 2024: $133 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $675.19 | 2019-2023 | Blincyto |
| Alexion Pharmaceuticals, INC. | $355.75 | 2019 | |
| Genentech USA, INC. | $307.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $236.61 | 2019-2020 | |
| Genzyme Corporation | $234.53 | 2022 | |
| Janssen Biotech, INC. | $226.94 | 2019-2025 | Carvykti, Rybrevant |
| Tactile Systems Technology INC | $155.76 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Celgene Corporation | $146.99 | 2019-2023 | Reblozyl |
| Astellas Pharma US INC | $136.79 | 2019-2022 | |
| Incyte Corporation | $125.70 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $116.40 | 2024 | Enhertu |
| Gilead Sciences, INC. | $111.60 | 2023 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $105.26 | 2019 | |
| Dova Pharmaceuticals | $103.82 | 2020 | |
| Exelixis INC. | $95.16 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $73.09 | 2023-2025 | Keytruda, Lynparza |
| Array Biopharma INC | $40.98 | 2022 | |
| Blueprint Medicines Corporation | $28.36 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.35 | 2022 | |
| Taiho Oncology, INC. | $19.65 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.89 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Appel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.